Tissue-specific promoters in gene therapy for the treatment of prostate cancer.
Delivery of therapeutic toxic genes to and their expression in tumor cells through the use of tissue-specific promoters could decrease their toxic effect on neighboring normal cells when virus-mediated gene delivery results in their infection. We have demonstrated the utility of two prostate cancer-specific promoters, long PSA and osteocalcin, for tissue-specific toxic gene therapy for prostate cancer. The two promoters were highly active in both androgen-dependent and androgen-independent prostate cancer cells. We also introduce the Phase I trial of osteocalcin promoter-based toxic gene therapy for bone metastases of prostate cancer, which is in progress at the University of Virginia.
Shirakawa
T
T
Department of Urology, Kobe University School of Medicine, Kobe, Japan. toshiro@kobe-u.ac.jp
Gotoh
A
A
Wada
Y
Y
Kamidono
S
S
Ko
S C
SC
Kao
C
C
Gardner
T A
TA
Chung
L W
LW
D000212:Acyclovir / Q000627:therapeutic use; D000818:Animals; D017321:Clinical Trials, Phase I as Topic; D015316:Genetic Therapy; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D015675:Osteocalcin / Q000235:genetics; D012516:Osteosarcoma / Q000235:genetics / Q000628:therapy; D011401:Promoter Regions, Genetic; D017430:Prostate-Specific Antigen / Q000235:genetics; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000473:pathology / Q000628:therapy*
D015675:Osteocalcin; D017430:Prostate-Specific Antigen; D000212:Acyclovir